These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 20022093)

  • 1. RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.
    Zhao Y; Zong ZH; Xu HM
    Gynecol Oncol; 2010 Mar; 116(3):563-71. PubMed ID: 20022093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2.
    Zhang A; Meng L; Wang Q; Xi L; Chen G; Wang S; Zhou J; Lu Y; Ma D
    Oncol Rep; 2006 Apr; 15(4):831-6. PubMed ID: 16525667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
    Wang P; Wu X; Chen W; Liu J; Wang X
    Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
    Hata K; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Miyazaki K
    Gynecol Oncol; 2004 Apr; 93(1):215-22. PubMed ID: 15047239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and clinical significance of endostatin and vascular endothelial growth factor in ovarian carcinoma].
    Shi HR; Song WJ; Chen ZM; Wu QH
    Ai Zheng; 2005 Sep; 24(9):1127-31. PubMed ID: 16159439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expressions of TGIF, MMP9 and VEGF proteins and their clinicopathological relationship in gastric cancer].
    Hu ZL; Wen JF; Shen M; Liu Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):70-4. PubMed ID: 16562680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer.
    Campos X; Muñoz Y; Selman A; Yazigi R; Moyano L; Weinstein-Oppenheimer C; Lara HE; Romero C
    Gynecol Oncol; 2007 Jan; 104(1):168-75. PubMed ID: 16935322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibitory effects of RNA interference on expression of matrix metalloproteinase-9 gene and invasiveness and adhesion in ovarian cancer cells].
    Hu XX; Li L; Li DR; Zhang W; Tang BJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):579-83. PubMed ID: 17181964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
    Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
    Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of vascular endothelial growth factor overexpression in ovarian tumor invasion and mechanism].
    Lu Y; Zhang A; Wang S; Li J; Wang C; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):294-7. PubMed ID: 12133405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
    Hata K; Osaki M; Dhar DK; Nakayama K; Fujiwaki R; Ito H; Nagasue N; Miyazaki K
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):68-74. PubMed ID: 14569416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9.
    Cheung LW; Leung PC; Wong AS
    Cancer Res; 2006 Nov; 66(22):10902-10. PubMed ID: 17108127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferation suppression and apoptosis of ovarian carcinoma cells induced by small interfering RNA against vascular endothelial growth factor.
    Zhou J; Gan N; Zhang W; Lu W; Xie X
    J Obstet Gynaecol Res; 2010 Apr; 36(2):232-8. PubMed ID: 20492371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
    Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
    Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia up-regulates the effects of prostaglandin E2 on tumor angiogenesis in ovarian cancer cells.
    Zhu G; Saed GM; Deppe G; Diamond MP; Munkarah AR
    Gynecol Oncol; 2004 Aug; 94(2):422-6. PubMed ID: 15297183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer.
    Stimpfl M; Tong D; Fasching B; Schuster E; Obermair A; Leodolter S; Zeillinger R
    Clin Cancer Res; 2002 Jul; 8(7):2253-9. PubMed ID: 12114428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas.
    Ueda M; Hung YC; Terai Y; Kanda K; Kanemura M; Futakuchi H; Yamaguchi H; Akise D; Yasuda M; Ueki M
    Clin Cancer Res; 2005 May; 11(9):3225-32. PubMed ID: 15867217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Correlation of expression of RhoA (RhoC and their effector ROCK-1 with malignant phenotype of ovarian cancer cells in vitro].
    Han ZQ; Zhang AL; Wu MF; Liu YL; Chen G; Li FJ; Gao QL; Liao GN; Lu YP; Wang SX; Ma D
    Zhonghua Zhong Liu Za Zhi; 2004 Jul; 26(7):385-8. PubMed ID: 15355639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
    Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF
    Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.
    Tsuchiya T; Nakahama K; Asakawa Y; Maemura T; Tanaka M; Takeda S; Morita M; Morita I
    Gynecol Endocrinol; 2009 Feb; 25(2):104-9. PubMed ID: 19253105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.